Philips to Further Expand its Image-Guided Therapy Devices Portfolio through Acquisition of Vesper Medical

PhilipsRoyal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, announced that it has signed an agreement to acquire Vesper Medical Inc., a US-based medical technology company that develops minimally-invasive peripheral vascular devices. Vesper Medical will further expand Philips' portfolio of diagnostic and therapeutic devices with an advanced venous stent portfolio for the treatment of deep venous disease. The transaction, which is subject to customary closing conditions, is expected to be completed in the first quarter of 2022. Financial details of the transaction were not disclosed.

Philips already has a leading peripheral vascular portfolio, consisting of: live 2D/3D interventional imaging combined with intravascular ultrasound (IVUS) catheters to provide the visualization and guidance essential for the optimal diagnosis and treatment; peripheral atherectomy devices to remove blockages; and peripheral therapy devices, including the Stellarex drug-coated balloon to treat lesions, and the Tack implantable dissection repair device that restores blood flow in small limb vessels, which Philips added to its offering through the acquisition of Intact Vascular in 2020. With this portfolio, Philips provides clinicians with a complete procedural solution for the treatment of peripheral artery disease (PAD).

Complementing Philips’ strong IVUS offering in venous imaging, Vesper Medical will add a venous stenting solution to address the root cause of chronic deep venous disease (DVD). The Vesper DUO Venous Stent System® consists of venous stents intended to treat deep venous obstruction. Uniquely engineered to address the multiple anatomical challenges of the deep venous system, it provides physicians with a modular portfolio to customize therapy, restore venous flow, and resolve the painful symptoms of deep venous disease for the broad range of patients suffering from chronic venous insufficiency.

"The acquisition of Vesper Medical is another step in our objective to innovate patient treatment with more sophisticated technology and expand our growth in the vascular therapy space," said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. "Leveraging our significant procedural expertise, we see strong clinical synergies between Vesper Medical's innovative stenting solution and our existing peripheral vascular offering. This combined offering will help to better support clinicians to decide, guide, treat and confirm during the procedure, thereby enhancing patient care."

"I am proud that Philips will become the home for our innovations and our people, joining forces to shape the future of treating deep venous disease," said Bruce Shook, President and CEO of Vesper Medical. "I look forward to further advance our next generation venous technology and bring it to patients and clinicians globally, together with Philips."

Vesper Medical was founded in 2016 and is headquartered in Wayne, Pennsylvania, US. Upon completion of the transaction, Vesper Medical and approximately 20 of its employees will become part of Philips' Image-Guided Therapy business.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum - from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 78,000 employees with sales and services in more than 100 countries.

Most Popular Now

Philips Foundation 2024 Annual Report: E…

Marking its tenth anniversary, Philips Foundation released its 2024 Annual Report, highlighting a year in which the Philips Foundation helped provide access to quality healthcare for 46.5 million people around...

New AI Transforms Radiology with Speed, …

A first-of-its-kind generative AI system, developed in-house at Northwestern Medicine, is revolutionizing radiology - boosting productivity, identifying life-threatening conditions in milliseconds and offering a breakthrough solution to the global radiologist...

Scientists Argue for More FDA Oversight …

An agile, transparent, and ethics-driven oversight system is needed for the U.S. Food and Drug Administration (FDA) to balance innovation with patient safety when it comes to artificial intelligence-driven medical...

New Research Finds Specific Learning Str…

If data used to train artificial intelligence models for medical applications, such as hospitals across the Greater Toronto Area, differs from the real-world data, it could lead to patient harm...

Giving Doctors an AI-Powered Head Start …

Detection of melanoma and a range of other skin diseases will be faster and more accurate with a new artificial intelligence (AI) powered tool that analyses multiple imaging types simultaneously...

AI Agents for Oncology

Clinical decision-making in oncology is challenging and requires the analysis of various data types - from medical imaging and genetic information to patient records and treatment guidelines. To effectively support...

Patients say "Yes..ish" to the…

As artificial intelligence (AI) continues to be integrated in healthcare, a new multinational study involving Aarhus University sheds light on how dental patients really feel about its growing role in...

Brains vs. Bytes: Study Compares Diagnos…

A University of Maine study compared how well artificial intelligence (AI) models and human clinicians handled complex or sensitive medical cases. The study published in the Journal of Health Organization...

'AI Scientist' Suggests Combin…

An 'AI scientist', working in collaboration with human scientists, has found that combinations of cheap and safe drugs - used to treat conditions such as high cholesterol and alcohol dependence...

Start-ups in the Spotlight at MEDICA 202…

17 - 20 November 2025, Düsseldorf, Germany. MEDICA, the leading international trade fair and platform for healthcare innovations, will once again confirm its position as the world's number one hotspot for...